INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 45h ago
HOUSE PTR5h ago
SEC 13F5h ago
ROBINHOOD CHAIN5h ago
SEC FORM 4/Grant or awardVerified data

Pershing Edward reported PVCT

Director, CEO · PROVECTUS BIOPHARMACEUTICALS, INC. · PROVECTUS BIOPHARMACEUTICALS, INC. — 8% Unsecured Convertible Promissory Note

Side
A
Value
—
Shares
—
Price
—
Executed
Nov 26, 2025
Disclosed
Nov 28, 2025
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Nov 26 executedNov 28, 2025 disclosed

PVCT · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
8/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size0 / 25

No reported dollar value

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · PVCT

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    8
    PE
    Pershing EdwardDirector, CEO, 10% Owner
    PVCTPROVECTUS BIOPHARMACEUTICALS, INC.
    Option exercise
    		M—Oct 23, 2026Oct 23, 2026
    traded Oct 23, 2026
    		+0dSEC FORM 4

    Evidence

    9
    PE
    Pershing EdwardDirector, CEO, 10% Owner
    PVCTPROVECTUS BIOPHARMACEUTICALS, INC.
    Option exercise
    		M—
    7,599 sh
    		Oct 23, 2026Oct 23, 2026
    traded Oct 23, 2026
    		+0dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001493152-25-025335
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Nov 26, 2025
    Published
    Nov 28, 2025
    Ingested by INSIDER
    Nov 5, 04:30 UTC
    Last re-read
    Nov 5, 04:30 UTC

    Extracted facts

    Filer
    Pershing Edward
    Role
    Director, CEO
    Transaction
    Grant or awardAs filed: “A”
    Asset
    PROVECTUS BIOPHARMACEUTICALS, INC. — 8% Unsecured Convertible Promissory Note
    Ticker
    PVCT
    Price per share
    $0
    Execution date (reported)
    Nov 26, 2025
    Days from execution to publication
    2

    What this establishes

    Pershing Edward filed this Form 4 reporting a grant or award of PVCT on Nov 26, 2025. It became public on Nov 28, 2025. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director, CEO
    Pershing Edwardcik:0001689739
    Issuer
    PROVECTUS BIOPHARMACEUTICALS, INC.cik:0000315545

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.